Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 13 Oct 2021
AstraZeneca COVID-19 vaccine will no longer be made in Australia
13 October 2021 - The AstraZeneca COVID-19 vaccine will no longer be manufactured in Australia due to the demand for ...
Posted by Michael Wonder on 13 Oct 2021
FDA approves pembrolizumab combination for the first-line treatment of cervical cancer
13 October 2021 - Today, the FDA approved pembrolizumab (Keytruda, Merck) in combination with chemotherapy, with or without bevacizumab, for ...
Posted by Michael Wonder on 13 Oct 2021
SMC accepts Cabometyx/Opdivo combo for advanced kidney cancer patients
13 October 2021 - The SMC has recommended Cabometyx (cabozantinib) plus Opdivo (nivolumab) for use by via NHS Scotland for ...
Posted by Michael Wonder on 13 Oct 2021
Scotland is first country to offer free digital therapies to every adult
13 October 2021 - The Scottish Government has announced that all Scottish adults will now have access to "digital therapeutics" ...
Posted by Michael Wonder on 13 Oct 2021
EU may consider deal on Merck's COVID pill after approval procedure begins
12 October 2021 - The European Union may consider signing a supply deal with U.S. drugmaker Merck for its experimental ...
Posted by Michael Wonder on 13 Oct 2021
FDA approves abemaciclib with endocrine therapy for early breast cancer
13 October 2021 - On 12 October 2021, the FDA approved abemaciclib (Verzenio, Eli Lilly) with endocrine therapy (tamoxifen or an ...
Posted by Michael Wonder on 13 Oct 2021
MHRA backs Merck’s MET inhibitor Tepmetko
13 October 2021 - The UK MHRA has conditonally authorised Merck’s MET inhibitor Tepmetko (tepotinib) for the treatment of certain ...
Posted by Michael Wonder on 13 Oct 2021
Provisional determination granted to Pfizer's COVID-19 vaccine (Comirnaty) - proposed for use in children 5-11 years of age
13 October 2021 - On 12 October 2021, the Therapeutic Goods Administration granted a provisional determination to Pfizer in relation ...
Posted by Michael Wonder on 12 Oct 2021
European authorities launch HTA network
12 October 2021 - On 29 September, the heads of 19 European HTA authorities met to launch a network for strategic ...
Posted by Michael Wonder on 12 Oct 2021
FDA’s accelerated approval program: is change on the way?
11 October 2021 - The U.S. FDA launched its accelerated approval program in 1992, offering a pathway to bring life saving ...
Posted by Michael Wonder on 12 Oct 2021
When is the Novavax vaccine coming to Australia? Will it be used for booster shots?
13 October 2021 - Australia's vaccination rate is galloping towards 85 per cent, and more than six in 10 Australians ...
Posted by Michael Wonder on 12 Oct 2021
NICE guidance on inclisiran should be reconsidered
12 October 2021 - Recommendation is premature without data on cardiovascular outcomes. ...
Posted by Michael Wonder on 12 Oct 2021
Deciphera announces approval of Qinlock in Switzerland for the treatment of fourth-line gastro-intestinal stromal tumour
12 October 2021 - Seventh approval worldwide for Qinlock and first European approval. ...
Posted by Michael Wonder on 12 Oct 2021
Outdated criteria for drug plan reimbursement obstruct evidence based care
12 October 2021 - An important flaw in the funding approach used by Canada’s public drug plans is highlighted by the ...
Posted by Michael Wonder on 12 Oct 2021
Where is the PHARMAC Review Panel’s interim report?
12 October 2021 - Patient advocacy groups and clinicians are calling out the PHARMAC Review Panel for failing to get their ...